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SUMMARY 
A prerequisite for the prolonged infusion of a drug via a totally implanted drug 
delivery system is that the drug solution must be sufficiently stable at physiological 
temperatures to endure the time intervals between drug replacement or pump refills. 
Consequently, the stability of the chemotherapeutic agents can influence the dosing 
accuracy and ultimately the achievement of the desired therapeutic goal. The chem- 
ical stability of the pharmaceutical preparation Trimetrexate (TMQ) glucuronate, a 
non-classical, lipophilic antifolate, has been character&d. Incubation of TMQ (pre- 
pared in sterile water to a concentration of 5.0 mg/ml) in sterile, amber glass vials at 
37°C for 56 days resulted in a degradation rate constant of 0.0134 + 0.002 day-’ and a 
half-life of 51.6 + 0.8 days. The major degradation product has been identified as 
(2,4-diamino-5-methyl-6-carboxaldehyde)quinazoline. Ten percent TMQ degrada- 
tion would occur by 7.9 days of incubation under these conditions. 
INTRODUCTION 
Trimetrexate, 2,4-diamino-5-methyl-6[(3,4,5-trimethoxyanilino)-methyl]quina- 
zoline (TMQ), was originally synthesized by Elslager and Davoll’. It is a potent 
inhibitor of dihydrofolate reductase (DHFR) [5,6,7,8-tetrahydrofolate:NADP+- 
oxido-reductase (EC 1.5.1.3)]‘, and has demonstrated significant antitumor activity 
against murine and human cell lines both in vitro and against several murine trans- 
planted tumors . 394 TMQ is more lipophilic than the classical antifolate methotrexate 
(MTX) and has demonstrated an increased uptake into neoplastic cells compared to 
MTXS. Also, TMQ’s enhanced lipophilicity may afford its greater penetration into 
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the central nervous system (CNS) and, therefore, greater efficacy than MTX against 
CNS neoplasms. 
The importance of antifolate concentration and exposure time in determining 
toxic and therapeutic effects both in vitro and in vivo in experimental animal tumors 
has been established6qg. Studies in experimental animal systems have also shown that 
biological response to antifolates is determined by exposure time and is selective for 
individual tissues”-“. These findings suggest a therapeutic rationale for the pro- 
longed infusion of TMQ at rigidly controlled dose rates which achieve steady-state 
TMQ plasma levels toxic to neoplastic cells but below the toxic threshold of bone 
marrow cells from that individual patient. With the advent of totally implanted drug 
delivery systems, therapy involving prolonged intravenous or, in the case of regional 
chemotherapy”, intra-arterial infusions can be accomplished on an out-patient 
basis with minimal patient risk and significant savings in hospital an patient care 
expenses. 
Portable drug delivery systems, both external and implanted, allow constant 
drug infusion rates at the desired sites for extended durations. However, a pre- 
requisite for prolonged drug infusion via a totally implanted drug delivery system is 
that the drug solution must be sufficiently stable at physiological temperatures to 
endure the time intervals between drug replacement or pump refills. Consequently, 
the stability of the chemotherapeutic agents can influence the dosing accuracy and 
ultimately the achievement of the desired therapeutic goal. The present study was 
designed to characterize the stability of the TMQ drug preparation (Trimetrexate 




Trimetrexate glucuronate (50 mg TMQ/vial) and 2,4-diamino-5-methyl-6-car- 
boxaldehyde-quinazoline (AMCQ) were obtained from Warner-Lambert/Parke-Da- 
vis, Pharmaceutical Research Devision, Ann Arbor, MI, U.S.A. All other chemicals 
were high-performance liquid chromatography (HPLC) or analytical grade. Amber- 
ized glass vials (10 ml capacity with rubber septa and crimp closures) and N-methyl- 
N-trimethylsilyltrifluoroacetamide (MSTFA) were obtained from Pierce (Rockford, 
IL, U.S.A.). Sterile plastic (1.0 ml) syringes (Becton, Dickinson & Co., Rutherford, 
NJ, U.S.A.) were used for sampling. 
Kinetic procedures 
Trimetrexate glucuronate injection (50-mg vial) was reconstituted in 10.0 ml 
sterile water to yield a concentration of 5.0 mg TMQ/ml. The reconstituted solution 
was aseptically transferred to sealed, sterile, amber glass vials. Triplicate sample solu- 
tions were prepared. A 0.2-ml aliquot of the samples was removed from each amber 
vial and signified the samples at zero time. The vials were then incubated in a con- 
stant-temperature water bath at 37°C and 0.2-ml aliquots were removed from each 
vial at the following times: 3, 10, 14, 17,21,25,28, 31,39,42,47,49 and 56 days. All 
samples were frozen immediately upon acquisition at - 30°C in tightly capped plastic 
tubes until TMQ analysis. 
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HPLC assay of TMQ 
TMQ standards, quality control and experimental (incubate) samples were di- 
luted 1:5 with methanol-water (5050, v/v) and 2.0 ~1 of the diluted samples were 
injected onto an HPLC reversed-phase column (Hewlett-Packard MOS Cs, 10 cm x 
2 mm I.D., 5 ,um) using the Hewlett-Packard Model 1090 high-performance liquid 
chromatograph and autosampler. The chromatographic conditions were: mobile- 
phase, methanol-acetonitrile-O.05 M (NH4)H2P04 buffer (12: 18:70, v/v/v); flow- 
rate, 0.5 ml/min; detector, Hewlett-Packard Model 1040 diode array UVVIS detec- 
tor monitoring at 254 nm wavelength and scanning between 200 and 400 nm. The 
chromatographic peak area integration was acquired using the Hewlett-Packard 
3392A integrator/printer. 
Calibration curves were constructed by plotting the integrated peak area of 
TMQ as a function of the drug concentration. The TMQ concentrations of unknown 
samples were calculated using the results of a least squares linear regression analysis 
of the calibration data. 
Gas chromatography-mass spectrometry 
The Hewlett-Packard Model 5987A gas chromatography-mass spectrometry 
(GC-MS) apparatus equipped with both electron impact (EI) and methane chemical 
ionization (CI) modes of operation was used in the identification of the major product 
of TMQ degradation. Separation of the trimethylsilyl (TMS) derivatives of TMQ and 
its degradation products was accomplished using a fused-silica capillary column (5 m 
x 0.32 mm I.D.) coated with a cross-linked methyl silicone liquid phase (0.17 mm 
film thickness). Chromatographic conditions were: injection port and GC-MS in- 
terface oven temperatures were 300°C; GC column oven temperature was pro- 
grammed to hold at the initial temperature of 80°C for 0.1 min, and then increase at a 
rate of 20”C/min up to the final temperature of 300°C; for EI operation, the ion source 
temperature was 25O”C, electron energy was 70 eV, and the scan range was from 70 to 
600 a.m.u.; for methane CI operation, the ion source temperature was 200°C electron 
energy was 230 eV, and the scan range was from 130 to 600 a.m.u. 
Trimethylsilylation of TMQ and its degradation products was accomplished 
using MSTFA. Aliquots of 0.1 ml of both the zero-time and 56-day incubation sam- 
ples were vacuum dried and the residue derivatized in 0.25 ml MSTFA for 2 h at 85°C. 
A 0.5~~1 volume of the reaction mixture was injected for GC-MS analysis. 
RESULTS AND DISCUSSION 
TMQ assay validation 
Under the described chromatographic conditions, the retention time of TMQ 
was 2.03 min. The integrated peak areas were directly proportional to the drug con- 
centrations over the range of TMQ concentrations tested (0.50-5.00 mg/ml). 
Triplicate sets of the calibration standards were assayed on each of three con- 
secutive days. Linear regression of the data from each day was obtained. The repro- 
ducibility of the daily standard curves had coefficients of variation which ranged 
between 1.7 and 4.8%. 
The accuracy and precision of the method were assessed by seeding quality 
control samples at drug concentrations of 1.00 and 4.00 mg TMQ/ml. Triplicate 
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Fig. 1. Results of peak purity evaluation of TMQ peak in HPLC assay procedure. Peak purity is confirmed 
by three perfectly superimposed UV-VIS absorption spectra. 
quality control samples were assayed on each of three consecutive days. The precision 
of the assay was found to have coefficients of variation ranging between 1.9 and 
4.4%. The concentration means for the seeded control samples were found to be 
within - 1.3- + 3.2% of the theoretical values. 
TMQ assay specljicity 
The purity of the TMQ peak in the HPLC assay described here was confirmed 
with a peak purity evaluation program available on the HP 1090 HPLC system 
equipped with the HP 1040 diode array detector. This program automatically col- 
lects UV-VIS absorption spectral data at the upslope, apex and downslope of an 
eluting peak. In the peak purity analysis, the upslope spectrum of a peak is recorded 
and becomes a reference spectrum. The apex spectrum of the peak then becomes the 
reference and the upslope spectrum is discarded. The downslope spectrum of the peak 
is then plotted against the reference (apex) spectrum. Finally, the end-of-peak spec- 
trum is plotted against the reference (apex) spectrum. Peak purity is established by 
three perfectly superimposed spectra. 
When applied to the TMQ incubation samples, three superimposed spectra 
t=zero time t=Zl days t=56 doys 
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Fig. 2. HPLC chromatograms (24 injections) of zero-time, 21-day and 56-day incubation samples show- 
ing TMQ (peak B) disappearance and degradation product (peak A) accumulation with increasing in- 
cubation time. 
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(Fig. 1) of the drug peak (peak B in Fig. 2) resulted, thus verifying that the TMQ peak 
was uncontaminated by any potentially coeluting products. 
Degradation kinetics 
The integrated peak areas of the incubated samples were compared to those 
resulting from injections of standard solutions. The concentration versus time (in 
days) data were then entered on semi-log plots as shown in Fig. 3. The stability profile 
of TMQ can be described by the simple monoexponential decay as given in eqn. 1: 
C, = Co exp( - kt) (1) 
where Co is the initial concentration at time zero, k is the rate constant for degrada- 
tion of TMQ in day-‘, t is the time in days, and C, is the concentration of TMQ at 
incubation time (t). The parameters of the least squares regression line for eqn. 1 are 
summarized in Table I. The mean ( f S.D.) rate constant for drug degradation was 
0.0134 f 0.0002 day-’ and, therefore, the mean half-life (0.693/k) for TMQ at 37°C 
in glass was 51.6 f 0.8 days. If one defines the maximum allowable percent drug loss 
before either drug replacement or pump refill as lo%, then the maximum allowable 
incubation (or infusion) time between TMQ refill or replacement based on the rate 
constant of degradation obtained in this study would be 7.9 days. 
Products of TMQ degradation 
Since the half-life of TMQ in this preparation at 37°C is only 51.6 days, the 
degradation product(s) would be expected to accumulate in significant amounts even 
in the relatively short incubation period of 1-2 weeks. Fig. 2 shows a chromatogram 
(HPLC) of TMQ samples (2.0 ~1 injections) from zero-time, 21-&y and 56-day in- 
cubations. It is evident from Fig. 2 that as the parent drug peak (B) progressively 
decreases with increasing incubation time, other earlier eluting peaks (primarily peak 
A) are increasing. It is to be noted that most of the early eluting peaks (including peak 
A) are absent or only marginally present in the zero-time or TMQ standard solutions. 
1I I 
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Fig. 3. TMQ concentration versus incubation time (in days). Data have been fitted to a monoexponentid 
equation of the form C, = C, exp( - kt), with the results: C, = (4.56 f 0.10) exp - (0.0134 f 0.0002)r and 
correlation coefficient r = 0.993 + 0.002. 
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TABLE I 
SUMMARY OF PARAMETERS OF THE LEAST SQUARES REGRESSION LINE FOR EQN. 1 





4.60 0.0136 51.0 
4.63 0.0135 51.3 
4.45 0.0132 52.5 
Mean f S.D. 4.56 f 0.10 0.0134 f 0.0002 51.6 + 0.8 
Using the diode array UV-VIS detector, UV spectral data were gathered for 
both TMQ and its major degradation product, peaks B and A in Fig. 2, respectively. 
These spectral data are shown in Fig. 4. The major degradation product has a dis- 
tinctly different UV spectrum, with an absorbance maximum at 253.nm and a second- 
ary peak at 332 nm. TMQ’s UV spectrum elicits two primary peaks at 215 and 243 nm 
and a small secondary peak at 330 nm. 
The GC-MS analysis of the vacuum-dried residues from the zero-time and 
56-day incubation samples derivatized with MSTFA revealed a large peak (tR = 5.0 
min) in the 56-day sample which was absent in the zero-time sample. Both samples 
had a large peak eluting at 9.2 min, corresponding to authentic TMQ-bisTMS. When 
analysed in the EI mode, the mass spectrum of TMQ-bisTMS (Fig. 5) displayed a 
molecular ion at m/z 513 and the typical TMS derivative fragmentation pattern with 
loss of a methyl group yielding [M - 15]+ at m/z 498, and the prominent [TMS]+ at 
m/z 73. The base peak at m/z 331 corresponds to cleavage at the anilino-methyl 
90x- 
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Fig. 4. UV-VIS absorption spectra of TMQ (peak B in Fig. 2), degradation product (peak A in Fig. 2), and 
authentic AMCQ. 








Fig. 5. EI mass spectrum of TMQ-bisTMS (peak B in Fig. 2). 
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Fig. 6. EI mass spectra of (a) trimethylsilylated degradation product (peak A in Fig. 2), and (b) authentic 
AMCQ-bisTMS. 
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linkage. The degradation product’s mass spectrum (Fig. 6a) suggests that its molec- 
ular ion is at m/z 346, and its base peak is [M - 15]+ at m/z 33 1, in this case due to loss 
of a methyl group from one of the TMS adducts. Also present were significant peaks 
at m/z 345 and 318 corresponding to the [M - l]+ and [M - CO]+ peaks which are 
characteristic of aromatic aldehydes. 
GC-MS analysis of these samples in the methane Cl mode resulted in base 
peaks of TMQ and its degradation product at the corresponding [M + I]+ ions (m/z 
514 and 347, respectively). Also characteristic of methane CI, each mass spectrum 
included an [M + 29]+ ion, due to the addition of (C2Hs). Finally, the fragmentation 
patterns were consistent with TMS derivatives showing a significant [M - 15]+ peak. 
The TMQ-bisTMS CI mass spectrum retained as its second largest peak the ion at 
m/z 331. 
Additional evidence for the presence of an aldehyde in the incubated samples 
was obtained with the 2,4_dinitrophenylhydrazine test for aldehydes and ketones14. 
The zero-time sample tested negative for aldehydes and ketones (no precipitate for- 
mation). However, the 56-day sample elicited a strong positive response with the 
immediate formation of an orange-red precipitate (the insoluble dinitrophenylhydra- 
zone). 
The mass spectral and chemical data suggested the identity of the degradation 
product as AMCQ. Mass spectral (Fig. 6) and UV-VIS absorption spectral (Fig. 4) 
analysis of authentic AMCQ confirmed this conclusion. 
In conclusion, the chemical stability of the pharmaceutical preparation (Tri- 
metrexate glucuronate) of this non classical antifolate has been evaluated. Incubation 
in sterile, amber glass vials at 37°C for 56 days resulted in a degradation rate constant 
of 0.0134 _+ 0.0002 day-’ and a half-life of 51.6 f 0.8 days. The major degradation 
product has been identified as AMCQ. Ten percent TMQ degradation would occur 
by 7.9 days of incubation under these conditions. Therefore, use of this drug prep- 
aration in implanted drug delivery systems would necessitate weekly pump refill or 
replacement if one sets 10% degradation as the maximum allowed. 
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